A toolmaker's perspective on CRISPR-directed gene editing as a therapeutic strategy for leukemia and beyond.
Expert review of hematology, 14(7): 587-592 PMID 34047246 DOI 10.1080/17474086.2021.1935853
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.